208 related articles for article (PubMed ID: 10223934)
1. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
2. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Alffenaar JW; van der Laan T; Simons S; van der Werf TS; van de Kasteele PJ; de Neeling H; van Soolingen D
Antimicrob Agents Chemother; 2011 Mar; 55(3):1287-9. PubMed ID: 21199931
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST
Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766).
Hoppe JE
J Chemother; 1999 Jun; 11(3):220-1. PubMed ID: 10435686
[No Abstract] [Full Text] [Related]
6. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages.
Sood R; Rao M; Singhal S; Rattan A
Int J Antimicrob Agents; 2005 Jun; 25(6):464-8. PubMed ID: 15885988
[TBL] [Abstract][Full Text] [Related]
7. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Yip PC; Kam KM; Lam ET; Chan RC; Yew WW
Int J Antimicrob Agents; 2013 Jul; 42(1):96-7. PubMed ID: 23684005
[No Abstract] [Full Text] [Related]
10. Antimycobacterial activities of oxazolidinones: a review.
Sood R; Bhadauriya T; Rao M; Gautam R; Malhotra S; Barman TK; Upadhyay DJ; Rattan A
Infect Disord Drug Targets; 2006 Dec; 6(4):343-54. PubMed ID: 17168800
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.
Wallis RS; Jakubiec WM; Kumar V; Silvia AM; Paige D; Dimitrova D; Li X; Ladutko L; Campbell S; Friedland G; Mitton-Fry M; Miller PF
J Infect Dis; 2010 Sep; 202(5):745-51. PubMed ID: 20629533
[TBL] [Abstract][Full Text] [Related]
12. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
Klemens SP; Cynamon MH
Antimicrob Agents Chemother; 1996 Feb; 40(2):298-301. PubMed ID: 8834869
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae.
Kearney JA; Barbadora K; Mason EO; Wald ER; Green M
Int J Antimicrob Agents; 1999 Jul; 12(2):141-4. PubMed ID: 10418759
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Wallis RS; Jakubiec W; Kumar V; Bedarida G; Silvia A; Paige D; Zhu T; Mitton-Fry M; Ladutko L; Campbell S; Miller PF
Antimicrob Agents Chemother; 2011 Feb; 55(2):567-74. PubMed ID: 21078950
[TBL] [Abstract][Full Text] [Related]
15. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
Schülin T; Thauvin-Eliopoulos C; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1999 Dec; 43(12):2873-6. PubMed ID: 10582874
[TBL] [Abstract][Full Text] [Related]
16. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
Williams KN; Brickner SJ; Stover CK; Zhu T; Ogden A; Tasneen R; Tyagi S; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Aug; 180(4):371-6. PubMed ID: 19520903
[TBL] [Abstract][Full Text] [Related]
17. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.
Dresser LD; Rybak MJ
Pharmacotherapy; 1998; 18(3):456-62. PubMed ID: 9620097
[TBL] [Abstract][Full Text] [Related]
18. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
Klemens SP; Grossi MA; Cynamon MH
Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
[TBL] [Abstract][Full Text] [Related]
19. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.
Bowersock TL; Salmon SA; Portis ES; Prescott JF; Robison DA; Ford CW; Watts JL
Antimicrob Agents Chemother; 2000 May; 44(5):1367-9. PubMed ID: 10770781
[TBL] [Abstract][Full Text] [Related]
20. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Periera R; Shrinivasan T; Iyyer R; Vishvanathan N; Rittel W
Diagn Microbiol Infect Dis; 1991; 14(6):465-71. PubMed ID: 1802533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
